Clinical trial · Interventional
Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine
NCT02580396CI-TRIAL-00035604completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This feasibility study will be conducted in order to provide proof of concept for the CanADVICE+® system comprising a smart phone app and a healthcare organization server side application based on Web 2 technologies. The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CanADVICE+® (smart phone app) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients eligible for CanADVICE+® (smart phone app)
- interventionNames
- Device: CanADVICE+® (smart phone app)
Primary outcomes (1)
- measure
- Patient acceptability of the app using questionnaire provided when patients attend for their 3rd cycle and quantified using a 5-point Likert scale
- timeFrame
- 42 days
- description
- The app will be used at cycles 1 and 2 of capecitabine (each cycle is 21 days), and acceptability of the app will be measured using a questionnaire when patients attend hospital for their 3rd cycle of capecitabine.
Secondary outcomes (2)
- measure
- Health care provider's acceptability of the app using questionnaires
- timeFrame
- 48 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with metastatic breast cancer * Commencing first cycle of Capecitabine * Familiar with and own an android smartphone * Willing to participate Exclusion Criteria: * Patients \<18 years * Patients taking part in any other trial containing Capecitabine * Chemotherapy-naïve patients
References
Publications (0)
Data not yet available
No reference posted for this study.